Biodexa Pharmaceuticals receives Fast Track designation for eRapa
Biodexa Pharmaceuticals (BDRX) received Fast Track status from the U.S. Food and Drug Administration for eRapa, a proprietary encapsulated form ...
Stocktwits on MSN4d
Biodexa Stock Surges On FDA's Fast-Track Tag For Treatment Of Cancer-Causing Condition: Retail Confidence Peaks
Shares of Biodexa Pharmaceuticals skyrocketed nearly 50% on Monday, hitting their highest level since early December. The ...
Biotech Alert: Searches spiking for these stocks today
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...
Following Positive Phase 2 Results and Orphan Drug Designation, Biodexa's FAP Drug Receives FDA Fast Track Status
CARDIFF, UK / ACCESS Newswire / February 12, 2025 /Biodexa Pharmaceuticals PLC. (NASDAQ:BDRX), a clinical-stage ...
Yahoo Finance1d
Biodexa Pharmaceuticals Plc (BDRX)
November 22, 2024 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Result of General Meeting Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) (NASDAQ: BDRX), a ...
Biodexa Pharmaceuticals ADRs Rise After Cancer Drug Gets FDA Fast-Track Designation
The U.K. biopharmaceutical company said data from a Phase 2 study of eRapa, a treatment for familial adenomatous polyposis, showed the drug to be safe and well-tolerated among users. The treatment ...
MT Newswires on MSN19h
European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading, Up 1% for Week
European equities traded in the US as American depositary receipts were trending modestly lower late Friday morning, down 0.23% to 1,399.64 on the S&P Europe Select ADR Index. Despite the decline, the ...
Nasdaq4d
Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis
Underscores unmet need for a therapeutic alternative with the potential to delay or prevent surgical removal of the colon and/or rectum Biodexa Pharmaceuticals PLC (“Biodexa” or “the Company ...
Nasdaq23d
Biodexa Pharmaceuticals Appoints Dr. Gary A. Shangold as Chief Medical Officer
Biodexa Pharmaceuticals PLC has announced the appointment of Dr. Gary A. Shangold as Chief Medical Officer, effective immediately. CEO Stephen Stamp expressed enthusiasm for Dr. Shangold’s ...
Biodexa Pharmaceuticals PLC: Following Positive Phase 2 Results and Orphan Drug Designation, Biodexa's FAP Drug Receives FDA Fast Track Status
CARDIFF, UK / ACCESS Newswire / February 12, 2025 / Biodexa Pharmaceuticals PLC. (NASDAQ:BDRX), a clinical-stage biopharmaceutical company developing a pipeline of innovative products for the treatmen ...